Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$795
in 4 filings, $795 under 10b5-1 plans

Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-05-15 Ege David S. Sale 10b5-1 −1,090 $0.94 $1K 75,734
2024-05-15 Ege David S. Exercise or conversion · Restricted Stock Units 10b5-1 −2,968 32,657
2024-05-15 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion 10b5-1 +2,656 123,233
2024-05-15 DesRosier Thomas Chief Legal Officer and EVP Sale 10b5-1 −843 $0.94 $792 122,390
2024-05-15 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion · Restricted Stock Units 10b5-1 −2,656 29,219
2024-04-04 Biondi Paul Director Grant or award · Stock Option (Right to Buy) +60,000 60,000
2024-04-04 Ausiello Dennis A Director Grant or award · Stock Option (right to buy) +60,000 60,000
2024-04-04 Fraser Claire Director Grant or award · Stock Option (right to buy +60,000 60,000
2024-04-04 Graves Kurt Director Grant or award · Stock Option (right to buy) +60,000 60,000
2024-04-04 Berenson Stephen Director Grant or award · Stock Option (Right to Buy) +60,000 60,000
2024-04-04 Dere Willard H Director Grant or award · Stock Option (right to buy) +60,000 60,000
2024-04-04 Kender Richard N Director Grant or award · Stock Option (right to buy) +60,000 60,000
2024-03-25 Thorell Marella Grant or award · Stock Options (right to buy) +700,000 700,000
2024-02-16 DesRosier Thomas Chief Legal Officer and EVP Sale 10b5-1 −3,939 $1.08 $4K 120,577
2024-02-16 Shaff Eric D. CEO and President Sale 10b5-1 −11,549 $1.08 $12K 135,321
2024-02-16 Henn Matthew R. Sale 10b5-1 −4,170 $1.08 $5K 63,436
2024-02-16 Young Teresa L. Sale 10b5-1 −3,374 $1.08 $4K 15,705
2024-02-16 von Moltke Lisa Sale 10b5-1 −4,400 $1.08 $5K 16,988
2024-02-16 Ege David S. Sale 10b5-1 −5,010 $1.08 $5K 73,856
2024-02-16 Arkowitz David Chief Financial Officer Sale 10b5-1 −3,939 $1.08 $4K 182,442

Page 14 of 23 · 458 trades